Perioperative Aspirin Management in Cardiovascular Disease Patients

Introduction to Aspirin Management

The American College of Chest Physicians recommends that aspirin should generally be continued or restarted as soon as possible after surgery in patients with established cardiovascular disease, typically within 24 hours once adequate hemostasis is achieved 1, 2

For patients with coronary artery disease, prior stroke, or peripheral arterial disease, aspirin should be restarted as soon as possible postoperatively, ideally within the first 24 hours, as discontinuation of antiplatelet therapy increases the absolute risk of stroke recurrence or cardiovascular events by approximately 2% within 30 days 2, 3, 4
In patients with coronary stents who required aspirin interruption, aspirin should be restarted immediately postoperatively and the P2Y12 inhibitor should be resumed as soon as possible, due to the high thrombotic risk in this population 1, 5

For most non-cardiac surgeries, aspirin can be safely restarted within 24 hours, but for high bleeding risk procedures such as neurosurgery, aspirin resumption should be delayed until the surgeon confirms adequate hemostasis and acceptable bleeding risk 2

The European Society of Cardiology and other guideline societies emphasize that aspirin should not be withheld indefinitely postoperatively in cardiovascular disease patients, as thrombotic events cluster early after discontinuation, with the highest risk in the first 30 days 3, 4
The American Heart Association recommends avoiding combination therapy with multiple antiplatelet or anticoagulant medications immediately postoperatively without careful risk assessment, as bleeding risk increases significantly with combination therapy 2
Medication reconciliation is crucial to ensure that patients are not taking over-the-counter NSAIDs with antiplatelet effects, which can impair aspirin's cardioprotective effects and increase bleeding risk 1, 2
For patients on dual antiplatelet therapy (DAPT), the timing of P2Y12 inhibitor resumption requires careful planning, as clopidogrel takes 4-5 days with maintenance dosing, prasugrel takes 3 days, and ticagrelor takes 2 hours to achieve maximal effect 1

The American College of Cardiology recommends that aspirin be continued throughout the perioperative period in patients with prior PCI, and if interrupted, should be restarted immediately postoperatively, with a strength of evidence based on high-quality trials 6, 7
In patients with drug-eluting stents (DES) placed less than 3 months ago or bare-metal stents (BMS) placed less than 30 days ago who require time-sensitive surgery, dual antiplatelet therapy (DAPT) should be continued unless bleeding risk outweighs stent thrombosis prevention, according to the American Heart Association guidelines 6, 7
The P2Y12 inhibitor should be resumed as soon as possible after surgery while maintaining aspirin throughout, as recommended by the American College of Cardiology 8

The American College of Cardiology recommends a maintenance dose of 75-100 mg daily for long-term secondary prevention, with a strength of evidence based on high-quality trials 6, 7

For patients taking aspirin for primary prevention who underwent noncardiac surgery, aspirin can be discontinued perioperatively and does not need to be restarted, as shown by the POISE-2 trial with a moderate strength of evidence 9, 8

American College of Cardiology (ACC)

European Society of Cardiology (ESC)

The NCCN guideline recommends stopping aspirin 7 days before a scheduled total knee replacement in patients whose ischemic stroke occurred more than 3 months earlier, allowing complete platelet turnover and normalization of platelet function before a high‑bleeding‑risk orthopedic procedure. 13

According to the NCCN guideline, aspirin should be restarted within 24 hours after surgery once the operating surgeon confirms adequate hemostasis and an acceptable bleeding risk. 13

The 2024 ESC guidelines advise using low‑dose aspirin 75–100 mg daily for chronic coronary syndromes, peripheral arterial disease, and secondary prevention after stroke; doses above 100 mg do not improve cardiovascular outcomes and increase gastrointestinal toxicity. [14][15]

For patients with recent stroke and symptomatic carotid stenosis, the 2024 ESC guidelines recommend dual antiplatelet therapy (aspirin + clopidogrel) for at least 3 months; during non‑cardiac surgery, clopidogrel may be held after the procedure while aspirin should be continued. [16][17]
The same ESC guidance reports that early combined aspirin and clopidogrel therapy reduces stroke recurrence in this population. [16][17]

Aspirin is a Class I indication for indefinite secondary‑prevention therapy after percutaneous coronary intervention (PCI) in patients with coronary artery disease. The American College of Cardiology/American Heart Association (ACC/AHA) guidelines assign a Class I recommendation to this practice. [18][19]
ACC/AHA guidelines explicitly require that aspirin be continued in patients with prior PCI and, if temporarily stopped, be restarted immediately after any surgical procedure. This is a Class I recommendation. 18

Advanced age (≥80 years), hypertension, moderate aortic stenosis, and a history of PCI together confer a high ischemic/thrombotic risk. 20
Recent major surgeries (e.g., head‑neck procedures) and acute kidney injury further increase cardiovascular risk during the early postoperative period. 18

Discontinuing aspirin in patients with established coronary disease markedly raises the short‑term risk of cardiovascular events, outweighing the modest increase in bleeding risk from concomitant SSRI use. This conclusion is supported by the cited evidence. 18

Continue low‑dose aspirin (75–100 mg daily) for secondary prevention after PCI, even when the patient is receiving an SSRI such as sertraline. The benefit‑risk balance favors continuation. 18
If bleeding concerns arise, add a proton‑pump inhibitor for gastro‑protection rather than stopping aspirin. (Guideline‑based gastro‑protection strategy.) 18
Do not replace aspirin with higher‑dose regimens (>100 mg) or add NSAIDs, as these measures increase bleeding without improving cardiovascular outcomes. 18
Do not discontinue aspirin solely because of SSRI initiation; the thrombotic risk of aspirin withdrawal exceeds the incremental bleeding risk of the SSRI‑aspirin interaction. 18
When the psychiatric indication for the SSRI is uncertain, consider tapering the SSRI rather than stopping aspirin, given the immediate thrombotic danger of aspirin interruption. 18